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Abstract
Background: Musculoskeletal pain is detrimental to quality of life (QOL) and disruptive to activities of daily living. It
also places a major economic burden on healthcare systems and wider society. In 2006, the Welsh Assembly
Government (WAG) established a three tiered self-referral Occupational Health Physiotherapy Pilot Project (OHPPP)
comprising: 1.) telephone advice and triage, 2.) face-to-face physiotherapy assessment and treatment if required,
and 3.) workplace assessment and a return-to-work facilitation package as appropriate. This study aimed to
evaluate the feasibility and cost-effectiveness of the pilot service.
Methods: A pragmatic cohort study was undertaken, with all OHPPP service users between September 2008 and
February 2009 being invited to participate. Participants were assessed on clinical status, yellow flags, sickness
absence and work performance at baseline, after treatment and at 3 month follow up. Cost-effectiveness was
evaluated from both top-down and bottom-up perspectives and cost per Quality Adjusted Life Year (cost/QALY)
was calculated. The cost-effectiveness analysis assessed the increase in service cost that would be necessary before
the cost-effectiveness of the service was compromised.
Results: A total of 515 patients completed questionnaires at baseline. Of these, 486 were referred for face to face
assessment with a physiotherapist and were included in the analysis for the current study. 264 (54.3%) and 199
(40.9%) were retained at end of treatment and 3 month follow up respectively. An improvement was observed at
follow up in all the clinical outcomes assessed, as well as a reduction in healthcare resource usage and sickness
absence, and improvement in self-reported work performance. Multivariate regression indicated that baseline and
current physical health were associated with work-related outcomes at follow up. The costs of the service were
£194-£360 per service user depending on the method used, and the health gains contributed to a cost/QALY of
£1386-£7760, which would represent value for money according to current UK thresholds. Sensitivity analyses
demonstrated that the service would remain cost effective until the service costs were increased to 160% per user.
Conclusions: This pragmatic evaluation of the OHPPP indicated that it was likely to be feasible in terms of service
usage and could potentially be cost effective in terms of QALYs. Further, the study confirmed that improving
physical health status for musculoskeletal pain patients is important in reducing problems with work capacity and
related costs. This study suggests that this type of service could be potentially be useful in reducing the burden of
pain and should be further investigated, ideally via randomised controlled trials assessing effectiveness and cost-
effectiveness.
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Background
The economic impact of pain is greater than most other
health conditions [1,2] due to its effects on rates of
absenteeism, reduced productivity and risk of leaving
the labour market. The indirect (productivity) cost of
back pain in the UK was estimated to be between £5
billion (€6.7 billion) and £10.7 billion (€14.4 billion) in
1998, depending on the approach employed [1]. The
average cost of sickness absence to industry was esti-
mated at £666 per employee per year in 2008 [3]. Of
this, musculoskeletal pain may represent as much as
49% of the total cost of sickness absence lasting longer
than 3 days [4].
A recent poll of members of the Chartered Institute
for Personnel Development found that after seasonal
coughs and colds, musculoskeletal conditions were the
foremost reason for short-term work absence in manual
workers and the second most common reason for long
term absences [3]. These data are supported by the find-
ings of a prospective study of work absence in a large
working population [5].
It has been estimated that as much as 77% of lost pro-
ductivity associated with pain relates to reduced perfor-
mance rather than work absence [6]. In addition, the
odds of quitting one’s job because of ill health have
been shown to be seven times higher among people
with chronic pain problems than those without [7]. In a
recent survey conducted in Wales, nearly 43% of
employees with a health condition in the previous 12
months, which they believed was caused or made worse
by work, identified a musculoskeletal pain condition [8].
Any condition caused or made worse by work falls
under the remit of Occupational Health (OH) services.
In 2005, the Welsh Assembly Government (WAG)
commissioned a mapping exercise to investigate the
level of OH activity across Wales [9]. One of the key
recommendations of the report was to explore opportu-
nities to support OH health care professionals by provi-
sion of physiotherapists to cover more of the
musculoskeletal workload. It should be noted that in the
United Kingdom, there is only one OH specialist
employed in every 35 medium-sized businesses (defined
as between 50 and 250 employees) and only 1 in every
1506 small businesses (less than 50 employees). The
National Health Service (NHS) is therefore the only OH
service available for many workers with musculoskeletal
pain [10].
There is evidence to support the effectiveness of com-
prehensive and integrated return to work packages
[11-13]. However, there is little evidence concerning the
practical implementation of this evidence into health
policy and clinical practice and few assessments of
whether such an approach is cost effective and there is
a dearth of studies investigating the cost effectiveness of
physiotherapy for musculoskeletal pain
This paper represents the establishment of a pilot pro-
ject of a physiotherapy service provided by three NHS
Trusts in Wales–Hywel Dda, Gwent and North West
Wales.a The self-referral service was made available to
public, private and third sector organisations and
included 47 small, medium and large employers repre-
senting a total of approximately 28,000 employees. The
aim of this paper is to report on the evaluation of the
programme pilot, focussing on feasibility and cost-
effectiveness.
Methods
Development of the service
The Occupational Health Physiotherapy Project Pilot
(OHPPP) service was provided in three stages:
• Physiotherapist telephone advice and triage to pro-
vide rapid, easily accessible advice and signposting to
relevant services;
• Physiotherapist face-to-face assessment and treat-
ment, arranged via telephone advice and triage if
deemed appropriate, to alleviate signs and symptoms of
musculoskeletal disorders (MSDs) and provided in hos-
pital, workplace, satellite clinics and other settings;
• Workplace assessment to provide essential informa-
tion to enable early return to work and resolution of a
slow-to-recover problem or a recurrent MSD, along
with assisting in overcoming fears associated with return
to work and informing the process of negotiating and
formulating a return to work package.
All employees of the organisations that had signed up
to take part in the scheme were informed of the OHPPP
service, primarily via leaflets that were provided to those
on sick leave and those in work. The leaflet outlined the
nature of the scheme and contained contact details for
the telephone advice line including operational hours.
The line was staffed by a qualified senior physiotherapist
with clinical experience in musculoskeletal conditions.
Patients provided with a face-to-face assessment and
workplace assessment were seen by a senior musculos-
keletal physiotherapist trained in Occupational Health
and Ergonomics. A job specification was set for phy-
siotherapists working alongside the senior physiothera-
pists on the project, who were clinical specialists,
extended scope practitioners, and some lower grade
staff, depending on the nature of clinical input being
provided. Training was provided for all staff involved at
each of the pilot sites covering aspects of Occupational
Health, work and ergonomics. The face-to-face assess-
ment and treatment part of the service was located
within NHS hospitals and in satellite clinics within the
relevant NHS Trust areas.
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Design and participants
A cohort study was undertaken, with all employees con-
tacting the OHPPP service between September 2008 and
February 2009 being invited to participate. At its incep-
tion it was estimated that approximately 150 people a
month would be expected to use the service and it was
estimated that of the users of the scheme:
• 64% would receive face to face assessment and
treatment
• 25% would be managed by advice alone
• 11% would be inappropriate
• 36% would receive work place assessments
It was therefore expected that roughly 96 people a
month would be referred on to further stages of the
intervention and the study was therefore set up to fol-
low consecutive referrals over a 12 week period to pro-
vide adequate data for the evaluation of the service.
However, it became apparent that uptake of the
scheme was not as had been anticipated and uptake
was 54% of what had been anticipated. All employees
that consented to participate were given questionnaires
at entry to the scheme (baseline), at end-of-treatment
and at 3-month follow-up, with the exception of
employees that were provided with telephone advice
only who were provided with questionnaires at entry
and 3 month follow-up only. Participant flow is shown
in Figure 1.
515 questionnaires were completed by service users, of
whom 29 received telephone advice only and 486 (94%)
were given a face to face hospital based and workplace
assessment if required. Due to the small number of par-
ticipants receiving telephone advice only, analysis on
pre- to post- change in outcome variables was restricted
to those who had received face to face treatment (n =
486). 264 (54.3%) were retained at end of treatment and
199 (40.9%) and 3 month follow up.
Measures
The questionnaires comprised a series of validated
instruments designed to assess the clinical, economic and
quality of life (QOL) effects of the scheme. Measures of
psychosocial risk factors, known as ‘yellow flags’ such as
fear, avoidance and catatrophizing were also included.
The questionnaire set included the following measures:
• Örebro Musculoskeletal Pain Questionnaire
(ÖMPQ) (at baseline only) [14]
Total patients 517
30 telephone
(1 Hywel Dda had 
hospital tx also)
488 assessed
for hospital tx
Hwl Dda
75
Hywel Dda
4
Gwent
9
North Wales 
17
North Wales
275
Gwent
138
48 at end of tx
35 at follow-up
76 at end of tx
53 at follow-up
143 at end of tx
115 at follow-up
3 at follow-up 7 at follow-up 13 at follow=up
Figure 1 OHPPP participant flow diagram.
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• Pain Catastrophising Scale [15]
• Fear Avoidance Beliefs Questionnaire (including
work and physical activity subscales) [16]
• Location specific pain measures [17-20]
- Roland Morris
- DASH (arm, shoulder and hand)
- Neck Disability
- Lower extremity
• Health related quality of life measures [21-23]
- EQ-5D (quality of life)
- SF-12 (including mental and physical health
subscales)
- GHQ (psychological distress)
Statistical analysis
Statistical analysis was carried out using PASW Statistics
Version 18. A descriptive analysis of the baseline charac-
teristics and demographic profile of the sample was carried
out, and comparisons between those who were retained or
lost to follow up was carried out using ANOVA and Cra-
mer’s V test as applicable to assess any potential systema-
tic bias in drop out. Changes in the Clinical, yellow flags
and work-related variables between baseline and end of
treatment and follow up were assessed using t-tests.
Due to the significant economic costs of the impact of
pain on work performance and absence, multivariate
regression analysis was carried out to assess whether
current health status and yellow flags were indepen-
dently associated with these outcomes at end of treat-
ment and follow up, adjusting for baseline scores on
these scales and demographics. Demographic variables
(age and sex), baseline and current clinical variables and
yellow flags (SF12 PCS & MCS, EQ-5D, GHQ, Pain
VAS, fear and avoidance beliefs) were entered in to the
models simultaneously using the ‘Enter’ command in
PASW. Missing data was excluded listwise.
Cost- effectiveness analysis
The cost-effectiveness of interventions is generally
assessed by way of an incremental cost effectiveness
ratio (ICER) versus usual standard care. An ICER takes
into account the costs and benefits of the two compara-
tive interventions. Benefits are often measured using
Quality Adjusted Life Years (QALYs), which take into
account both length and quality of life. In so doing, the
QALY enables comparison across a wide range of inter-
ventions with different outcomes. QALYs are utilised in
the cost-effectiveness analyses assessed by the National
Institute of Health and Clinical Excellence (NICE).
Cost-effectiveness is determined according to whether
the cost/QALY is within acceptable limits according to
the funding/decision making body. For NICE, the will-
ingness-to-pay threshold is often understood to be
around £20K-£30K/QALY, where interventions with an
ICER which exceeds this threshold, deemed not to a
cost-effective use of NHS resources. The cost-effective-
ness of OHPPP was assessed from the perspective of the
UK NHS and therefore indirect costs have not been
included. Given that the participants also acted as their
own controls, the comparator was basically what would
be usual care and practice. The cost-effectiveness was
assessed over a period of 12 months, based on assump-
tions regarding duration of benefits. Cost data were pro-
vided by WAG–based on budgetary and expenditure
records–and from published unit cost data. Effects were
derived from the findings relating to clinical and QOL
impacts of the scheme. The costs associated with
OHPPP were derived from both top-down and bottom-
up perspectives. The top down approach was employed
to relate the agreed budgeted expenditure to each ser-
vice provided by the NHS sites, while published unit
cost data was used in conjunction with resource usage
to derive cost estimates of specific services from a bot-
tom-up perspective. A series of sensitivity analyses were
undertaken to assess the effects of variations in costs
and outcomes and their impact on the findings of the
evaluation.
Results
A summary of the characteristics of the 486 participants
at baseline is provided in Table 1. Responders for all
three assessments were compared to those lost to follow
up after baseline or end of treatment were compared on
age, duration of pain complaint, SF12 physical and men-
tal health sores, GHQ, EQ5D, and pain. Cramer’s V
tests for the categorical variables indicated that those
lost to follow up did not differ from responders in gen-
der, income band, work status over the last 6 months,
or pain site. Baseline scores on the outcome variables
are provided in Table 2. The only differences found
between completers and non-completers at follow up
were in age (F = 9.53, df 2, 473, p < 0.001) and EQ-5D
score (F = 3.51, df 2, 479, p < 0.05). Post-hoc Bonferroni
tests indicated that those completing all three assess-
ments had higher EQ5D scores than those who com-
pleted baseline and end of treatment assessments, and
those completing all three assessments were older than
those completing only baseline or baseline and post
treatment assessments.
Change in clinical, psychosocial and work-related
variables
Means and standard deviations for the clinical, psycho-
social and work related variables at baseline, end of
treatment and follow up along with significant
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differences from baseline are shown in Table 2. Statisti-
cally significant changes in the expected direction were
observed for all of these target variables.
Statistically significant models emerged in multivariate
regression analysis for all four sets of analysis; days
sickness absence at end of treatment (F = 3.06, df 17, 222,
p < 0.001, Adjusted R2 = 12.6%) and at 3 month follow up
(F = 3.31, df 17, 151, p < 0.001, Adjusted R2 = 18.9%), and
work performance at end of treatment (F = 7.40, df 17,
220, p < 0.001, Adjusted R2 = 31.5%) and 3 month follow
up (F = 4.43, df 17, 154, p < 0.001, Adjusted R2 = 25.4%).
Beta values and 95% Confidence Intervals for the variables
entered in to the models are provided in Table 3.
Healthcare utilization
Of the 197 respondents who completed questionnaires
at all time points, 96 (48.7%) reported that they had uti-
lised healthcare services at baseline compared with 24
(12.2%) at end of treatment and 23 (11.7%) at follow up
(p < 0.001). There was also a significant reduction in
summary score for pain between baseline and end of
treatment (p < 0.001) and at follow-up (p < 0.001).
Service uptake rates and cost of service provision
The agreed expenditure for the three sites was based on
estimates of demand during the establishment of the
scheme, which were that approximately 150 people would
contact the service each month with a conversion rate of
around 64% to face-to-face contact. The actual demand
for the scheme was only 54% of what had been anticipated,
whilst the conversion rate of telephone consults into face
to face assessments was 94%. All the service users who
received a workplace assessment had first received both
telephone advice and a face-to-face assessment.
Based on contact times provided during discussions
with service providers it has been estimated that the
cost per service user contact hour would be in the
region of £46. This compared with the published unit
cost of £40 per service user hour (including training of
staff involved), shown in Table 4.
Table 2 Mean and standard deviation of outcome variables at baseline, end of treatment and 3 month follow up
Variable Baseline End of treatment Follow up
Clinical
Pain intensity VAS 10.54 (9.4) 7.42 (8.5)*** 6.91 (9.4)***
GHQ 12.95 (6.1) 9.76 (4.6)*** 10.11 (5.7)***
SF-12 mental health 52.32 (11.2) 55.52 (8.5)*** 55.81 (8.5)***
SF-12 physical health 42.18 (8.5) 48.86 (7.2)*** 50.97 (7.5)***
EQ-5D 0.66 (0.2) 0.82 (0.2)*** 0.82 (0.2)***
Yellow flags
Pain Catastrophizing 10.54 (9.41) 7.42 (8.54)*** 6.91 (9.4)***
Fear and avoidance - work 9.79 (9.5) 7.92 (8.3)*** 8.18 (8.6)***
Fear and avoidance - physical activity 11.81 (6.4) 8.31 (6.5)*** 7.63 (6.0)***
Work-related
Sickness absence 4.6 (12.6) 2.82 (11.4)* 1.45 (9.7)*
Work performance 75.9 (19.6) 82.1 (16.2)*** 87.8 (13.2)***
Statistically significant difference from baseline scores at end of treatment and follow-up using paired samples t-tests are denoted by *p < 0.05, **p < 0.01, ***p
< 0.001
Table 1 Baseline characteristics of participants referred
for face-to-face assessments (N = 486)
Variable N (%)
Gender Male 175 (36)
Female 306 (63)
Missing 5 (1)
Job type Managerial/supervisory 79 (16.3)
Non-manual 284 (58.4)
Manual 121 (24.9)
Missing 2 (0.4)
Work situation - past 6
months
Usual hours and duties 344 (72.3)
Usual hours but not usual
duties
44 (9.2)
Usual duties but not usual
hours
11 (2.3)
Usual hours but help needed 69 (14.5)
Not worked during
treatment
8 (1.7)
Missing 10 (2.1)
Pain site Back
Neck
Arms, shoulders, and/or
hands
Lower extremities
Mean (SD)
Age 43.10
(10.45)
Pain duration (months) 56.12
(91.1)
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While the original budget estimates were a consider-
able over-estimate in terms of demand, the conversion
rates to face to face consultations is likely to have limited
the discrepancy between estimated and actual costs of
delivering the service. The calculated unit cost per service
user hour amounted to £86–1.87 times the estimated
amount. Based on the assumptions relating to cost per
hour, it is estimated that the cost per user receiving the
OHPPP service amounted to between £194 (when the
bottom-up approach was employed) and £360 (based on
the top-down approach from WAG expenditure).
Cost-effectiveness analysis
The extent of the benefits highlighted in the previous sec-
tion indicates the relative success of the scheme in relation
to economic effects, clinical benefits and QOL gains. For
Table 3 Multivariate regression for associations with sickness absence and work performance at end of treatment and
follow up
End of treatment 3 month follow up
Β 95% CIs b 95% CI
Days sickness absence (last 6 months)
Baseline
Age -0.12* -0.24, -0.01 -0.05 -0.19, 0.09
Gender -0.72 -3.00, 1.56 1.70 -1.12, 4.52
SF-12 PCS -0.27** -0.44, -0.10 -0.05 -0.24, 0.15
SF-12 MCS -0.05 -0.22, 0.14 -0.17 -0.39, 0.04
EQ-5D 1.66 -5.46, 8.77 1.07 -7.43, 9.57
GHQ -0.18 -0.49, 0.13 0.05 -0.32, 0.42
Pain VAS -0.11 -0.28, 0.07 -0.21* -0.41, -0.01
OREBRO 0.08* 0.001, 0.15 -0.06 -0.15, 0.03
Fear and Avoidance Beliefs - Work 0.11 -0.37, 0.04 -0.16 -0.34, 0.03
Fear and Avoidance Beliefs - Physical Activity -0.17 -0.25, 0.14 0.10 -0.15, 0.35
Current status
SF-12 PCS -0.05 -0.25, 0.14 -0.35** -0.58, -0.11
SF-12 MCS -0.08 -0.28, 0.13 0.007 -0.24, 0.25
EQ-5D 4.18 -4.28, 12.64 -3.23 -12.18, 5.71
GHQ 0.17 -0.18, 0.51 0.92 -0.29, 0.47
Pain VAS -0.06 -0.23, 0.11 0.91 -0.10, 0.28
Fear and Avoidance Beliefs - Work -0.04 -0.22, 0.15 0.18 -0.02, 0.38
Fear and Avoidance Beliefs - Physical Activity 0.18 -0.05, 0.41 0.13 -0.13, 0.41
Work performance (last 30 days)
Baseline
Age 0.04 -0.13, 0.21 -0.12 -0.30, 0.07
Gender 2.27 -1.24, 5.77 -0.97 -4.65, 2.71
SF-12 PCS 0.32* 0.06, 0.58 0.03 -0.22, 0.28
SF-12 MCS 0.23 -0.05, 0.50 0.01 -0.27, 0.30
EQ-5D 4.84 -6.05, 15.73 -4.38 -15.43, 6.67
GHQ 0.07 -0.41, 0.55 0.27 -0.21, 0.76
Pain VAS 0.08 -0.19, 0.35 -0.19 -0.46, 0.07
OREBRO 0.05 -0.06, 0.16 -0.05 -0.16, 0.07
Fear and Avoidance Beliefs - Work -0.10 -0.37, 0.16 0.09 -0.16, 0.33
Fear and Avoidance Beliefs - Physical Activity 0.16 -0.16, 0.47 0.05 -0.27, 0.38
Current status
SF-12 PCS 0.85*** 0.55, 1.15 0.53** 0.22, 0.84
SF-12 MCS 0.27 -0.04, 0.59 0.25 -0.07, 0.58
EQ-5D -5.43 -18.43, 7.58 4.03 -8.08, 16.14
GHQ -0.52 -1.04, 0.02 -0.44 -0.93, 0.06
Pain VAS 0.09 -0.17, 0.35 -0.02 -0.27, 0.24
Fear and Avoidance Beliefs - Work -0.15 -0.43, 0.13 -0.20 -0.46, 0.07
Fear and Avoidance Beliefs - Physical Activity -0.25 -0.60, 0.10 0.12 -0.23, 0.46
NB: Values shown to 2 decimal places. * p < 0.05, **p < 0.01, ***p < 0.001
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example, the gain in health status between baseline and
follow-up (3 months after end of treatment) was 0.14 as
measured by EQ-5D, which translates to a gain of 0.047
QALYs, if the beneficial effect was terminated at follow-
up. If it is assumed that the beneficial effect was sustained
for a longer period of time, (e.g. 12 months), then the
QALY gain would amount to 0.14 per employee.
In this case, the estimated cost/QALY would be between
£1386 (when cost = £194 and QALY gain = 0.14) and
£7660 (when cost = £360 and QALY gain = 0.047) and
would be well within the bounds of cost/QALY estimates
considered–by the National Institute of Health and Clini-
cal Excellence (NICE) and other assessment agencies–to
represent value for money. In order for the cost/QALY to
be equivalent to NICE’s cost-effectiveness threshold of
£20,000, there would have to be an increase of 160% in the
cost per user, using highest cost estimate or a reduction of
62% in the QALY gained, using the lower utility estimate
derived from the EQ5D responses. As an alternative
approach, if one assumes that the value society place on a
QALY is equivalent to £25,000, then the net benefit (i.e.
total benefits minus total costs) generated by OHPPP is
between £3,140 and £13,806 per employee participant.
Discussion
Rationale for the scheme
There is good evidence that an early intervention
approach to the management of musculoskeletal disor-
ders can prevent work loss in those who are sympto-
matic and reduce the time to return to work for those
who absent from work [24-26]. There is also increasing
evidence that early intervention approaches, particularly
those that address return to work can be cost effective
for employers, health purchasers and providers of wage
replacement benefits [27-30].
Numerous systematic and narrative reviews have con-
cluded that early treatment for musculoskeletal pain pro-
blems can reduce work-loss and improve the patient’s
chances of rehabilitation and sustained retention in work
[31]. The evidence that physical therapy interventions
alone are effective in returning people to work is
equivocal [32]. One previous study demonstrated early
referral to physiotherapy was more effective than usual
care [33]. However, the provision of appropriate work-
place assessments and the incorporation of recommenda-
tions from such an assessment by way of modified duties
may help the worker return to work sooner [12,34,35].
Providing active rehabilitation, rather than simply the
provision of symptomatic relief (analgesia and manual
therapies), is an effective way of speeding up return to
work and reducing work loss in the longer term [36].
The aim of the current intervention was to provide
symptomatic relief where required, but to focus on
active rehabilitation to assist the person to return to
work. The basic elements of an active rehabilitation pro-
gramme include; advice on activity management includ-
ing work, graded physical exercise, and early resumption
of avoided or ceased activities using a cognitive beha-
vioural approach [37]. Numerous reviews of the litera-
ture [35,36,38-40] have indicated that this is the most
effective and cost-effective way to help workers with
musculoskeletal pain problems from a variety of diag-
noses. Guidance and recommendations from NICE
relating to the management of long-term sickness
absence and incapacity reflect such evidence [41].
Service uptake
Uptake rates for this service were lower than expected,
with around half of the anticipated number of service
users contacting OHPP. However, the vast majority of
people contacting the service were referred for face-to-
face treatment. Uptake for the workplace assessments,
however, was also lower than expected. Approximately
2-3% of the employees at participating organisations
contacted the service over the 8 month period when the
evaluation was being conducted. The vast majority of
people with acute musculoskeletal pain (approximately
98%) spontaneously recover relatively quickly [32,38],
and therefore the rate of contact with the OHPP service
may reflect this. This may have meant that those with
more minor or self-limiting complaints did not require
the telephone advice to the extent that had been
Table 4 Costs of Service Provision
Staff time
(hrs)
Cost based on published hourly rate
(£)*
Cost based on budgeted expenditure (£)
***
Actual Cost
(£)
Telephone 0.75 30 34.66 64.56
Face to face 4 160 184.87 344.31
Workplace 6 (inc travel) 273 277.30 516.47
Unit cost per hour 40** 46.22 86.08
Unit cost per service
user
168.00 194.00 360.00
*Curtis L. Unit costs of health and social care (p.195) 2010. http://www.pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf
**including qualifications
***Based on Welsh Assembly Government estimates of expenditure
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anticipated. Indeed, the average pain duration of partici-
pants in this study was 56 months indicating that they
had persistent problems.
The Welsh Backs initiative, promoting awareness of
recommendations for the self-management of muscu-
loskeletal pain for both members of the public and
health professionals, had been taking place around the
time that this service was introduced and therefore
this may also have influenced the way in which the
OHPP service was used. It is also possible that tele-
phone advice alone could have been sufficient for
some of the service users referred for face to face con-
tact. The lack of referrals for workplace assessments
could have been due to a number of reasons, such as
the availability of OH services in the participating
workplaces and possibly reluctance on the part of the
clinicians and service users to take the management of
what they perceived to be a clinical problem in to a
workplace setting. It is possible that further education
and training would be required to increase uptake of
this component of the service.
In summary, these findings suggested that in terms of
adoption and implementation of the service, the face-to-
face hospital based contact was most successful, with lit-
tle demand for telephone advice alone or workplace
assessments. The reasons for this would need further
investigation if the service were to be rolled out.
Change in outcomes and cost-effectiveness
As this was a cohort study and no control group was
included, it is not possible to conclude to what extent to
which changes observed were due to spontaneous recov-
ery as opposed to being a result of the intervention.
Nonetheless, statistically significant improvements were
observed in all the outcomes shown in Table 2 between
the baseline and follow up assessments. Current health
status had the strongest association with work-related
variables and association was stronger for work perfor-
mance than for absence, which was similar to findings
from a previous study conducted by some of the authors
[42,43], and highlights the importance of managing MS
pain effectively.
Furthermore, cost-effectiveness analyses indicate that
this service could potentially be provided at an accepta-
ble cost for the level of benefit yielded. The analysis
indicated that the service would continue to be cost-
effective until the cost per user increased by 160%.
Furthermore, it would be anticipated that once such a
service becomes established and the uptake increases
the cost per case would reduce.
It should be noted that the wider societal effects asso-
ciated with reduced sickness benefits costs, reduced
costs to employers attributed to improved production
and reduced absence rates were not included in the cur-
rent analysis. Sickness absence and presenteeism in par-
ticular are associated with significant economic costs
[3,4]. However, we did examine associations with work
performance and absence at follow up and end of treat-
ment within the cohort using multivariate regression
analysis. This indicated that physical health status was
particularly important in understanding impaired work
capacity at follow up. Current physical health status
(independently of baseline physical health) had the
strongest association with work performance and
absence at 3 month follow up, confirming the impor-
tance of timely and effective management of musculos-
keletal pain in reducing its burden.
Methodological issues
First and foremost, it must be stressed that this evalua-
tion employed a pragmatic cohort design and was not
based on a Randomised Controlled Trial (RCT). This
means that it is not possible to state that the benefits
seen were due to the intervention employed (the
OHPPP scheme). Nonetheless, a cohort design is a prag-
matic approach to initial evaluation of clinical practice,
and this study indicate that there was change in the
relevant variables in the expected direction and that it
could potentially be cost-effective. This suggests that
further investigation using an RCT is warranted
Despite regular and on-going marketing of the
scheme, the level of engagement by employers and ser-
vice users was considerably less than had been antici-
pated when the scheme was being established. This had
an impact on participant numbers resulting in the
extension of the recruitment period from 12 weeks to 7
months. Furthermore, many service users failed to
return follow-up questionnaires. These issues are impor-
tant in terms of the representativeness of the sample
and ability to generalise from the findings and improv-
ing engagement and minimising attrition are important
issues for further trials of such interventions.
Conclusions
This study demonstrated that that the OHPP is feasible
and has the potential to represent good value for
money. It is the first study to present cost effectiveness
data from physiotherapy intervention involving a part-
nership between the NHS and employers, and it is well
within the thresholds considered to indicate relative
cost-effectiveness for the UK National Health Service
(NHS). Despite the methodological issues, there are
grounds for considering that OHPPP is feasible as a ser-
vice and has met the objectives posed for the pilot
scheme. Improvement was observed across a range of
validated clinical measures in the quality of life of
Phillips et al. BMC Musculoskeletal Disorders 2012, 13:29
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service users, and in work related outcomes (absence
and performance). These results strongly suggest that
the scheme has potential to be beneficial and cost effec-
tive and further trial(s) of such initiatives that include
appropriate control groups would be warranted with an
assessment of wider societal costs.
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